HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Trastuzumab-containing therapy is a standard of care for patients with HER2+ breast cancer. HER2 status is routinely assigned using in situ hybridization to assess HER2 gene amplification, but interpretation of in situ hybridization results may be challenging in tumors with chromosome 17 polysomy or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern pathology 2014-01, Vol.27 (1), p.4-18
Hauptverfasser:	Hanna, Wedad M, Rüschoff, Josef, Bilous, Michael, Coudry, Renata A, Dowsett, Mitch, Osamura, Robert Y, Penault-Llorca, Frédérique, van de Vijver, Marc, Viale, Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/2489/144/68 692/699/67/1347 692/699/67/2329 Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer therapies Centromere chromosome 17 Chromosomes Chromosomes, Human, Pair 17 Clinical medicine FDA approval Female Gene Amplification Gene Dosage Genetic Heterogeneity Genetic Predisposition to Disease HER2 testing Hospitals Humans Hybridization In Situ Hybridization Laboratory Medicine Medical prognosis Medicine Medicine & Public Health Metastasis Oncology Pathology Patient Selection Phenotype polysomy Precision Medicine Predictive Value of Tests Protein Kinase Inhibitors - therapeutic use Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism review-article Trastuzumab Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!